In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso

Vito Baraka, Halidou Tinto, Innocent Valea, Robert Fitzhenry, Christopher Delgado-Ratto, Martin K Mbonye, Chantal Van Overmeir, Anna Rosanas-Urgell, Jean-Pierre Van Geertruyden, Umberto D'Alessandro, Annette Erhart

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Abstract

Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number1
Pages (from-to)734-737
Number of pages4
ISSN0066-4804
DOIs
Publication statusPublished - 2015

Fingerprint

Dive into the research topics of 'In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso'. Together they form a unique fingerprint.

Cite this